CoreCap Advisors
RPRX icon

CoreCap Advisors’s Royalty Pharma RPRX Stock Holding History

CoreCap Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$51.1K Hold
876
– – ﹤0.01% 1390
2026
Q2 		$49.1K Buy
876
+413
+89% +$21.5K ﹤0.01% 1414
2026
Q1 		$22.2K Buy
463
+400
+635% +$17.5K ﹤0.01% 1624
2025
Q4 		$2.43K Buy
+63
New +$2.4K ﹤0.01% 2430
2024
Q3 		– Sell
-73
Closed -$1.92K – 2727
2024
Q2 		$1.92K Buy
+73
New +$2.02K ﹤0.01% 1326

Other funds holding RPRX

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Hosking Partners
Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return
Kepler Cheuvreux
Kepler Cheuvreux Nyon $1.65B AUM 36.86% 1-Year Est. Return
Foster Victor Wealth Advisors
Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return
Kirr Marbach & Co
Kirr Marbach & Co Columbus, Indiana $530M AUM 14.37% 1-Year Est. Return
Triasima Portfolio Management
Triasima Portfolio Management Montreal, Quebec, Canada $758M AUM 48.16% 1-Year Est. Return
Fideuram - Intesa Sanpaolo Private Banking
Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return

CoreCap Advisors's RPRX Position: Q3 2026 in Review

CoreCap Advisors held its Royalty Pharma (RPRX) position steady in Q3 2026 at 876 shares worth $51.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1390.

CoreCap Advisors first reported a position in RPRX in Q2 2024 and has held it in 5 quarters since. 129 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • CoreCap Advisors held 876 shares of Royalty Pharma worth $51.1K as of Q3 2026.
  • CoreCap Advisors left its Royalty Pharma share count unchanged in Q3 2026.
  • Royalty Pharma made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #1390 holding.
  • CoreCap Advisors first reported a position in Royalty Pharma in Q2 2024 and has held it in 5 quarters since.
  • 129 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.